Abstract:High-throughput screening (HTS) has achieved a dominant role in drug discovery over the past 2 decades. The goal of HTS is to identify active compounds (hits) by screening large numbers of diverse chemical compounds against selected targets and/or cellular phenotypes. The HTS process consists of multiple automated steps involving compound handling, liquid transfers, and assay signal capture, all of which unavoidably contribute to systematic variation in the screening data. The challenge is to distinguish biologically active compounds from assay variability. Traditional plate controls-based and non-controls-based statistical methods have been widely used for HTS data processing and active identification by both the pharmaceutical industry and academic sectors. More recently, improved robust statistical methods have been introduced, reducing the impact of systematic row/column effects in HTS data. To apply such robust methods effectively and properly, we need to understand their necessity and functionality. Data from 6 HTS case histories are presented to illustrate that robust statistical methods may sometimes be misleading and can result in more, rather than less, false positives or false negatives. In practice, no single method is the best hit detection method for every HTS data set. However, to aid the selection of the most appropriate HTS data-processing and active identification methods, the authors developed a 3-step statistical decision methodology. Step 1 is to determine the most appropriate HTS data-processing method and establish criteria for quality control review and active identification from 3-day assay signal window and DMSO validation tests. Step 2 is to perform a multilevel statistical and graphical review of the screening data to exclude data that fall outside the quality control criteria. Step 3 is to apply the established active criterion to the quality-assured data to identify the active compounds.

Frequent Hitters: Nuisance Artifacts in High-Throughput Screening

Benchmarking the Mechanisms of Frequent Hitters: Limitation of PAINS Alerts.

Hit screening with multivariate robust outlier detection

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

Development and Application of Activity-based Fluorescent Probes for High-Throughput Screening

ChemFH: an integrated tool for screening frequent false positives in chemical biology and drug discovery

Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery

Optimal design for high-throughput screening via false discovery rate control

Design and Implementation of High Throughput Screening Assays for Drug Discoveries

Increasing the Odds of Drug Hit Identification by Screening Against Receptor Homologs?

Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening

Online Phenotype Discovery in High-Content Rnai Screens Using Gap Statistics

A deep-learning based analysis framework for ultra-high throughput screening time-series data

Unleashing high content screening in hit detection - Benchmarking AI workflows including novelty detection

Bayesian Multi Plate High Throughput Screening of Compounds

Identifying Actives from HTS Data Sets: Practical Approaches for the Selection of an Appropriate HTS Data-Processing Method and Quality Control Review

Pattern Recognition in Mining High-Throughput Genomics/Proteomics Data: The New Challenges in Old Questions

Machine Learning-Driven Data Valuation for Optimizing High-Throughput Screening Pipelines

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery